Last reviewed · How we verify
Dexemedetomidine
At a glance
| Generic name | Dexemedetomidine |
|---|---|
| Sponsor | The Cooper Health System |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dexemedetomidine on Shivering Cesarean Section Under Spinal Anesthesia A Randomized Clinical Trial (NA)
- Dexmedetomidine in Postoperative Analgesia (PHASE2, PHASE3)
- The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption (NA)
- Emergency Delirium in Pediatrics Undergoing Tonsillectomy and Adenoidectomy (EARLY_PHASE1)
- The Effect of Intraperitoneal Injection of Magnesium Sulphate Versus Dexmedetomidine as an Adjuvant to Bupivacaine on Postoperative Analgesia in Patients Undergoing Abdominal Aortic Surgery (NA)
- Dexmedetomidine in IVRA (PHASE4)
- Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
- Rapid Sequence Induction: Succinyl Choline vs Rocuronium After Pretreatment With Dexmedetomidine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexemedetomidine CI brief — competitive landscape report
- Dexemedetomidine updates RSS · CI watch RSS
- The Cooper Health System portfolio CI